3000+ Attendees, 450 Speakers, 12 Conference Tracks, 100+ Posters
 
MMTC15_Header  
MMTC M Header 

Cambridge Healthtech Institute’s Inaugural

Genomic Technologies for Patient Stratification

Unlocking New Markers to Ensure Successful Treatment

February 16-18, 2015 | Moscone North Convention Center | San Francisco, CA
Part of the 22nd Annual Molecular Medicine Tri-Conference

 

Early patient stratification is critical to enable effective and personalized drug discovery and development. Genomic Technologies for Patient Stratification will showcase novel technologies and techniques that are being used by researchers to stratify patient populations into an appropriate trial. Emphasis will be placed on identifying and generating new biomarker leads to maximize the chances of successful treatment. The importance of high-speed and accurate methods for marker detection will also be examined, and case studies using new techniques and technologies to take advantage of a patient's genotype will be showcased. Attendees will come away with the knowledge and tools to move forward in the rapidly advancing area of personalized medicine.

NGS-DRIVEN NEXT-GENERATION STRATIFIED TRIALS

Lung MAP Trial: Protocol Design and Stratification Techniques

David Gandara, M.D., Professor of Medicine, Division of Hematology/Oncology, University of California, Davis School of Medicine; Director, Thoracic Oncology Program, Senior Advisor to the Director, UC Davis Comprehensive Cancer Center; Chair, Lung Committee, Southwest Oncology Group (SWOG)

The Evolving Genotype-to-Phenotype Paradigm in Oncology Drug Development

Steffan N. Ho, M.D., Ph.D., Senior Director, Early Development, Translational Oncology, Pfizer Oncology

NGS-Based Companion Testing in Biomarker-Driven Clinical Trials

Shirin Khambata Ford, Ph.D., Executive Director, US Hematology and Oncology Medical Affairs, Celgene Corporation


RNA SEQ FOR PATIENT STRATIFICATION

Genetic Profiling of Hematologic Malignancies

Ross L. Levine, M.D., Associate Member, HOPP; Associate Attending, Leukemia Service; Memorial Sloan-Kettering Cancer Center

Sequencing Approaches for Personalized Cancer Therapy Selection and Monitoring

Daniela Starcevic, Ph.D., Director, Diagnostic Sequencing; Assistant Professor, Genomics and Multiscale Biology; Assistant Professor, Pathology; Icahn School of Medicine at Mount Sinai

Clinical Trials for Precision Oncology Using Next-Generation Sequencing

Sameek Roychowdhury, M.D., Ph.D., Assistant Professor, Internal Medicine, Medical Oncology, Pharmacology, Comprehensive Cancer Center, Ohio State University


PCR FOR PATIENT STRATIFICATION

Digital PCR for Patient Monitoring and Stratification in Clinical Trials

Reinhold Pollner, Ph.D., Director, Clinical Trial Assay Development, Genoptix Medical Laboratory, a Novartis Company

Evaluation of EGFR Mutations in Plasma from NSCLC Patients: Utility in Managing Patients on TKI Therapy

Chris Karlovich, Ph.D., Principal Scientist, Molecular Diagnostics, Clovis Oncology


PATIENT RECRUITMENT USING BIOMARKER ANALYSIS TOOLS

Demonstration of the Utility of Point-of-Care Genotyping Technologies to Actively Recruit into Genotype Stratified Studies

Charles Cox, Ph.D., Head, Genetics Experiment Design and Delivery, GlaxoSmithKline

Survival Improvement by Personalized Genomic Diagnostics for Ovarian Cancer Chemotherapy

Jae Lee, Ph.D., Chair and Senior Member, Biostatistics and Bioinformatics, Moffitt Cancer Center


LOOKING BEYOND THE DIRECT MOLECULAR TARGETS OF DRUGS

Molecular and Clinical Predictors of Disease Status, Trajectory and Treatment Response Enabling Patient Stratification

Jaya Goyal, Ph.D., Director, Value Based Medicine, Biogen Idec

Contextualization of Individualized Patient Molecular Profiles Enabling Patient Stratification and Association with Distinct Clinical Characteristics

Ahmed Enayetallah, M.D., Ph.D., Senior Scientist, Value Based Medicine, Biogen Idec


UNLOCKING NEW MARKERS FOR STRATIFICATION

Orion Bionetworks, a Novel Cooperative Partnership for Systems Modeling and Biomarker Discovery for Brain Diseases

Magali Haas, M.D., Ph.D., Founder and Chief Executive Officer, Orion Bionetworks

The Impact of Tumor Heterogeneity on Clinical Biomarker Development using FFPE Tissue

Ken Chang, Ph.D., Senior Principal Scientist, Molecular Biomarkers and Diagnostics, Merck Clinical Labs

Identifying and Overcoming Markers of Chemoresistance

Jason Baum, Ph.D., Associate Director, Companion Diagnostics, Research, Merrimack Pharmaceuticals



For more details on the conference, please contact:
Samantha Lewis
Conference Director
Cambridge Healthtech Institute
T: (+1) 781-972-5461
E: slewis@healthtech.com 

For partnering and sponsorship information, please contact: 

Jon Stroup (Companies A-K)
Manager, Business Development
Cambridge Healthtech Institute
T: (+1) 781-972-5483
E: jstroup@healthtech.com 

Joseph Vacca (Companies L-Z) 
Manager, Business Development
Cambridge Healthtech Institute
T: (+1) 781.972.5431
E: jvacca@healthtech.com
 

 


  2015 Plenary Sessions 


2015 MMTC Prelim Agenda 

Premier Sponsors:

 

Elsevier 


Jackson Laboratory - small logo 

Leica Biosystems 
 

 NanoString2   

 

Singulex